SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Spinar J)
 

Search: WFRF:(Spinar J) > (2020-2021) > Omecamtiv mecarbil ...

  • Teerlink, John R.Univ Calif San Francisco, USA; Univ Calif San Francisco, USA (author)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-10-27
  • WILEY,2020
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-171398
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-171398URI
  • https://doi.org/10.1002/ejhf.2015DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Amgen, Inc.Amgen; Cytokinetics; ServierServier
  • Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction <= 35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m(2) (n = 528), and treated with sacubitril/valsartan at baseline (n = 1594). Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Diaz, RafaelEstudios Clin Latino Amer ECLA, Argentina (author)
  • Felker, G. MichaelDuke Univ, NC USA; Duke Clin Res Inst, NC USA (author)
  • McMurray, John J. V.Univ Glasgow, Scotland (author)
  • Metra, MarcoASST Spedali Civili, Italy; Univ Brescia, Italy (author)
  • Solomon, Scott D.Brigham & Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA (author)
  • Adams, Kirkwood F.Univ N Carolina, NC 27515 USA (author)
  • Anand, InderUniv Minnesota, MN USA (author)
  • Arias-Mendoza, AlexandraInst Nacl Cardiol, Mexico (author)
  • Biering-Sorensen, TorUniv Copenhagen, Denmark; Univ Copenhagen, Denmark (author)
  • Bohm, MichaelSaarland Univ, Germany (author)
  • Bonderman, DianaMed Univ Vienna, Austria (author)
  • Cleland, John G. F.Imperial Coll, England; Univ Glasgow, Scotland (author)
  • Corbalan, RamonPontificia Univ Catolica Chile, Chile (author)
  • Crespo-Leiro, Maria G.Univ A Coruna, Spain (author)
  • Dahlström, UlfLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)ulfda85 (author)
  • Echeverria Correa, Luis E.Fdn Cardiovasc Colombia, Colombia (author)
  • Fang, James C.Univ Utah, UT USA (author)
  • Filippatos, GerasimosUniv Athens, Greece (author)
  • Fonseca, CandidaCHLO, Portugal; Univ Nova Lisboa, Portugal (author)
  • Goncalvesova, EvaComenius Univ, Slovakia (author)
  • Goudev, Assen R.Queen Giovanna Univ Hosp & Med Univ, Bulgaria (author)
  • Howlett, Jonathan G.Univ Calgary, Canada; Univ Calgary, Canada (author)
  • Lanfear, David E.Henry Ford Heart & Vasc Inst, MI USA (author)
  • Lund, MayannaMiddlemore Hosp, New Zealand (author)
  • Macdonald, PeterSt Vincents Hosp Sydney, Australia (author)
  • Mareev, VyacheslavUniv Clin Lomonosov Moscow State Univ, Russia (author)
  • Momomura, Shin-ichiSaitama Citizens Med Ctr, Japan (author)
  • OMeara, EileenMontreal Heart Inst, Canada; Univ Montreal, Canada (author)
  • Parkhomenko, AlexanderInst Cardiol, Ukraine (author)
  • Ponikowski, PiotrWroclaw Med Univ, Poland (author)
  • Ramires, Felix J. A.Univ Sao Paulo, Brazil (author)
  • Serpytis, PranasVilnius Univ, Lithuania (author)
  • Sliwa, KarenUniv Cape Town, South Africa (author)
  • Spinar, JindrichUniv Hosp Brno, Czech Republic (author)
  • Suter, Thomas M.Univ Bern, Switzerland (author)
  • Tomcsanyi, JanosSt John God Hosp, Hungary (author)
  • Vandekerckhove, HansAZ St Lucas, Belgium (author)
  • Vinereanu, DragosUniv Med & Pharm Carol Davila, Romania (author)
  • Voors, Adriaan A.Univ Groningen, Netherlands (author)
  • Yilmaz, Mehmet B.Dokuz Eylul Univ, Turkey (author)
  • Zannad, FaiezUniv Lorraine, France (author)
  • Sharpsten, LucieAmgen Inc, CA 91320 USA (author)
  • Legg, Jason C.Amgen Inc, CA 91320 USA (author)
  • Abbasi, Siddique A.Amgen Inc, CA 91320 USA (author)
  • Varin, ClaireServier, France (author)
  • Malik, Fady I.Cytokinetics Inc, CA USA (author)
  • Kurtz, Christopher E.Amgen Inc, CA 91320 USA (author)
  • Univ Calif San Francisco, USA; Univ Calif San Francisco, USAEstudios Clin Latino Amer ECLA, Argentina (creator_code:org_t)

Related titles

  • In:European Journal of Heart Failure: WILEY22:11, s. 2160-21711388-98421879-0844

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view